<DOC>
	<DOCNO>NCT02070731</DOCNO>
	<brief_summary>A randomized evaluation TriGuard™ HDH embolic deflection device transcatheter aortic valve implantation .</brief_summary>
	<brief_title>DEFLECT III : A Prospective , Randomized Evaluation TriGuard™ HDH Embolic Deflection Device During TAVI</brief_title>
	<detailed_description>The TriGuard HDH device aortic embolism deflection device intend reduce amount embolic material may enter carotid , subclavian , vertebral artery transcatheter heart valve implantation . To assess safety , efficacy , performance TriGuard HDH embolic deflection device patient undergoing transcatheter aortic valve implantation ( TAVI ) , comparison patient undergo unprotected TAVI . Subjects indication TAVI meet study eligibility criterion randomize 1:1 one two treatment arm : - Intervention - TAVI TriGuard HDH embolic deflection device - Control - standard unprotected TAVI</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>The patient male nonpregnant female ≥18 year age Patient meet indication TAVI The patient willing comply protocolspecified followup evaluation The patient , legally authorize representative , informed nature study , agree provision provide write informed consent , approve appropriate Medical Ethics Committee ( EC ) Institutional Review Board ( IRB ) Patients undergoing TAVI via transaxillary , transsubclavian , transaortic route Patients undergo TAVI via transapical approach due friable mobile atherosclerotic plaque aortic arch Pregnant nursing subject plan pregnancy period 1 year follow index procedure . Female subject childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test Patients know diagnosis acute myocardial infarction ( AMI ) within 72 hour precede index procedure ( accord definition ) AMI &gt; 72 hour precede index procedure , creatine kinase creatine kinaseMuscle Brain return within normal limit time procedure . Patients currently experience clinical symptom consistent newonset AMI , nitrateunresponsive prolong chest pain Patients history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate , refuse transfusion Patients know mental physical illness know history substance abuse may cause noncompliance protocol , confound data interpretation , associate life expectancy le one year Patients severe allergy heparin know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel , nitinol , stainless steel alloy , and/or contrast sensitivity adequately premedicated Patients history stroke transient ischemic attack ( TIA ) within prior 6 month Patients active peptic ulcer history upper gastrointestinal ( GI ) bleeding within prior 6 month Patients renal failure ( estimate Glomerular Filtration Rate [ estimate Glomerular Filtration Rate ] &lt; 30 mL/min , calculate serum creatinine CockcroftGault formula ) Patients hepatic failure ( ChildPugh class C ) Patients hypercoagulable state correct additional periprocedural heparin Patients present cardiogenic shock severe hypotension ( systolic blood pressure &lt; 90 mm Hg ) time index procedure Patients severe peripheral arterial disease precludes delivery sheath vascular access Patients heavily calcify severely atheromatous aortic arch Patients innominate artery ostium diameter &lt; 11 mm Patients transverse aortic diameter &gt; 40 mm Patients anatomic irregularity aortic arch innominate artery could prevent position stability device Patients contraindication cerebral MRI Patients plan treatment investigational device procedure study period Patients plan undergo cardiac surgical interventional procedure ( e.g. , concurrent coronary revascularization ) TAVI procedure within two ( 2 ) week prior TAVI procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>TAVR</keyword>
	<keyword>TAVI</keyword>
	<keyword>Aortic Valve Stenosis</keyword>
</DOC>